Eli Lilly advanced its “triple-G” obesity program as additional Phase 3 results cleared the path toward a U.S. regulatory filing for retatrutide. The company reported top-line readouts across two obesity trials that also enrolled patients with type 2 diabetes and cardiovascular complications. In the obesity-and-diabetes study (Triumph-2) and the severe obesity-and-cardiovascular-disease study (Triumph-3), retatrutide demonstrated sustained weight-loss endpoints at multiple dose levels over 80 weeks. Lilly is now looking to submit a BLA early next year, positioning the asset for potential competition against established incretin-based therapies. Analysts framed the dataset as reinforcing retatrutide’s differentiation within the incretin portfolio, while also noting that the degree of cardiovascular risk reduction remains a key open question ahead of review.